

Physician Insert: Cystic Fibrosis Clinical Sequencing Assay

FOR IN VITRO DIAGNOSTIC USE

Test Indication

This test is indicated to aid in the diagnosis of patients with suspected cystic fibrosis (CF). This test is most appropriate when a patient has an atypical presentation of CF or when other mutation variant panels have failed to identify both causative variants. The results of the test should be used in conjunction with clinical symptoms, other diagnostic tests, and family history.



CAUTION

This test is not intended for newborn screening, carrier screening, population screening, or for stand-alone diagnostic purposes. This test is not intended for fetal diagnostic testing or pre-implantation testing.

What the Test Detects

- ▶ This test performs targeted sequencing at 5206 genomic positions/regions in the Cystic Fibrosis Transmembrane Conductance Regulator (*CFTR*) gene in DNA isolated from whole blood collected in K₂EDTA.
- ▶ All protein coding regions in the *CFTR* gene including 10 nt of flanking intronic sequence are detected for all exons with the exception of three (exons 7, 10, and 20).
 - ▶ For exon 7 and exon 10, only 5 nt of flanking intronic sequence is included at the 5' end of the exon to avoid proximal homopolymeric InDels.
 - ▶ For exon 20, 30nt of flanking intronic sequence is included at the 5' end of the exon to enable detection of the mutation 3272-26A>G.
- ▶ In addition, the assay also detects ~100 nt of flanking sequence at the 5' and 3' UTRs, 2 deep intronic mutations (1811+1.6kbA>G, 3489+10kbC>T), 2 large deletions (CFTRdele2,3, CFTRdele22,23) and the PolyTG/PolyT region.
- ▶ The test detects single base changes and small insertions and deletions within the *CFTR* gene region sequenced.
- ▶ The test has not been validated for any other deletions or insertions greater than 3 bp in size.

Test Interpretation and Limitations

- ▶ Test results should be interpreted by board-certified clinical molecular geneticist or equivalent.
- ▶ Variants in *CFTR* identified by this test may be CF-disease causing, non-disease causing, or of unknown significance.
- ▶ There is substantial variability in phenotype among patients, even those with the same genotype. Expected disease presentation associated with certain variants may be based on a few clinical cases and may range from benign to severe. Rare *CFTR* variants may be poorly characterized and clinical significance may not have been assessed.
- ▶ If more than one variant is detected in a sample, the assay cannot determine phase or haplotype of the variants.
- ▶ It is recommended that patients consult with a genetic counselor regarding their results.

- ▶ It was not possible to validate all rare and novel variants that could be detected in the *CFTR* gene by this test. Therefore, it is highly recommended that novel or rare variants be confirmed by a reference method, such as Sanger sequencing. Discuss variant detection validation with the testing laboratory.
- ▶ This test sequences specific regions of the *CFTR* gene including all coding regions and certain other areas deemed clinically relevant. However, some regions of the gene are not covered. Thus an overall “wild-type” result does not guarantee that *CFTR* variants are not present in the sample.
- ▶ Variants which could be identified by this test vary in frequency in the population. Be aware that for very rare *CFTR* variants, the possibility of false positive findings is increased.



NOTE

For more information about the clinical significance of a large number of *CFTR* variants that may be detected by this test, refer to the *Cystic Fibrosis 139-Variant Assay Physician Insert (part # 15052172)*.

Patents and Trademarks

This document and its contents are proprietary to Illumina, Inc. and its affiliates ("Illumina"), and are intended solely for the contractual use of its customer in connection with the use of the product(s) described herein and for no other purpose. This document and its contents shall not be used or distributed for any other purpose and/or otherwise communicated, disclosed, or reproduced in any way whatsoever without the prior written consent of Illumina. Illumina does not convey any license under its patent, trademark, copyright, or common-law rights nor similar rights of any third parties by this document.

The instructions in this document must be strictly and explicitly followed by qualified and properly trained personnel in order to ensure the proper and safe use of the product(s) described herein. All of the contents of this document must be fully read and understood prior to using such product(s).

FAILURE TO COMPLETELY READ AND EXPLICITLY FOLLOW ALL OF THE INSTRUCTIONS CONTAINED HEREIN MAY RESULT IN DAMAGE TO THE PRODUCT(S), INJURY TO PERSONS, INCLUDING TO USERS OR OTHERS, AND DAMAGE TO OTHER PROPERTY, AND WILL VOID ANY WARRANTY APPLICABLE TO THE PRODUCT(S).

ILLUMINA DOES NOT ASSUME ANY LIABILITY ARISING OUT OF THE IMPROPER USE OF THE PRODUCT(S) DESCRIBED HEREIN (INCLUDING PARTS THEREOF OR SOFTWARE).

© 2020 Illumina, Inc. All rights reserved.

All trademarks are the property of Illumina, Inc. or their respective owners. For specific trademark information, see www.illumina.com/company/legal.html.

AMPure, Beckman, and Beckman Coulter are trademarks or registered trademarks of Beckman Coulter, Inc.

Contact Information



Illumina
5200 Illumina Way
San Diego, California 92122 U.S.A.
+1.800.809.ILMN (4566)
+1.858.202.4566 (outside North America)
techsupport@illumina.com
www.illumina.com



Illumina Netherlands B. V.
Freddy van Riemsdijkweg 15
5657 EE Eindhoven
The Netherlands

Australian Sponsor

Illumina Australia Pty Ltd
Nursing Association Building
Level 3, 535 Elizabeth Street
Melbourne, VIC 3000
Australia